However, Imfinzi/Imjudo fell short by 4%. Other significant results included Symbicort, which saw a 21% increase, and Ultomiris, up by 7%. Farxiga's performance was in line with consensus. AstraZeneca ...

Other significant results included Symbicort, which saw a 21% increase, and Ultomiris, up by 7%. Farxiga's performance was in line with consensus. AstraZeneca has raised its financial guidance for ...

including five of AstraZeneca’s patents on its blockbuster inhaler Symbicort. The company noted it reduced the list price of Symbicort at the start of this year. The change comes amid increasing ...

including five of AstraZeneca’s patents on its blockbuster inhaler Symbicort. The company noted it reduced the list price of Symbicort at the start of this year. Biden to sign executive order to ...

AstraZeneca substantially reduced the list price of SYMBICORT on January 1, 2024. The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled ...

Photo: Aaron M. Sprecher (AP) AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at ...

Starting June 1, 2024, eligible patients will pay no more than $35 per month for the following AstraZeneca inhalers: Airsupra, Bevespi Aerosphere, Breztri Aerosphere, and Symbicort. The savings ...

President – Sales & Marketing, Mankind Pharma Limited said “We are excited to partner with AstraZeneca to make their innovative therapy flagship brand Symbicort, a global standard in treating ...

Shares in AstraZeneca were down nearly 4% on the London Stock Exchange on Thursday morning after reporting its latest financial results. The Anglo-Swedish biopharmaceutical company reported $45 ...

AstraZeneca is in hot water with the U.K ... ruled that the Big Pharma made some serious errors of judgement for a Symbicort ad. The case was brought by an anonymous healthcare professional ...

AstraZeneca (AZN) shares climbed more than 4% in early trading on Friday after the company reported higher-than-expected revenue on strong sales of its cancer drugs and said it would acquire ...